Quick Answer
ANI PHARMACEUTICALS INC reported Research And Development Expense of $51.66 million for the year ending 2025.
- ANI PHARMACEUTICALS INC showed an increase of +15.9% in Research And Development Expense from 2024 to 2025.
- This data is from ANI PHARMACEUTICALS INC's annual report (Form 10-K), filed with the SEC on February 27, 2026.
- XBRL data for this metric is available from 2009 to 2025 (17 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 17 years of available data (2009 to 2025), ANI PHARMACEUTICALS INC's Research And Development Expense has grown by 277.6%.
- Historical annual values: Fiscal year 2025: $51.66 million | Fiscal year 2024: $44.58 million | Fiscal year 2023: $34.29 million | Fiscal year 2022: $22.32 million | Fiscal year 2021: $11.37 million | Fiscal year 2020: $16.00 million | Fiscal year 2019: $19.81 million | Fiscal year 2018: $15.39 million | Fiscal year 2017: $9.07 million | Fiscal year 2016: $2.91 million | Fiscal year 2015: $2.87 million | Fiscal year 2014: $2.68 million | Fiscal year 2013: $1.71 million | Fiscal year 2012: $1.16 million | Fiscal year 2011: $44.18 million | Fiscal year 2010: $39.71 million | Fiscal year 2009: $13.68 million.
- Data sourced from SEC EDGAR public filings as of June 22, 2026.
Last verified: